SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jargonweary who wrote (62833)9/26/2024 6:54:59 PM
From: erickerickson5 Recommendations

Recommended By
erippetoe
Fitzhughlaw
idahoranch1
jargonweary
summer_sky

   of 63324
 
re: Trodelvy

I'm catching up on my Scientific American back-issues and in the February issue there's an article about ADCs and Trodelvy gets a passing mention.

-------------
...Trodelvy was better irrespective of how much or how little TROP2 was detected on tumors. "That, to me, was wild," Tolaney says. "We're excited about it because these cancers are having benefits [apparently] without the target."
-----------

this is in a discussion about, you guessed it, different linkers and the "bystander effect".

We knew that all along ;) Well, some of us (not me) did...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News